Zimmer Biomet Holdings, Inc. ZBH
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, Zimmer Biomet Holdings, Inc. gets an algorithmic score of 60/100. It trades at 91.34 $, with a sideways/transition technical trend (RSI 40.5) and 32.2% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (8.2%).
- Low valuation (P/E 10.1).
- Low beta (0.36): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 22.17 |
| Forward P/E | 10.07 |
| PEG | 0.57 |
| P/B | 1.38 |
| EV/EBITDA | 9.73 |
| P/S | 2.05 |
| ROE % | 6.41 |
| ROA % | 3.88 |
| Gross margin % | 69.52 |
| Operating margin % | 17.96 |
| Net margin % | 9.48 |
| Revenue growth % (y/y) | 4.80 |
| Earnings growth % (y/y) | 33.80 |
| Revenue CAGR % | 5.85 |
| Earnings CAGR % | 44.98 |
| Debt/Equity % | 60.17 |
| Current ratio | 1.69 |
| FCF yield % | 8.15 |
| Dividend yield % | 1.05 |
| Payout % | 23.30 |
Returns
| 1 month | -9.5 % |
| 3 months | +6.1 % |
| 6 months | +3.6 % |
| YTD | +2.0 % |
| 1 year | -6.0 % |
| 3 years | -19.6 % |
| 5 years | -31.2 % |
Risk
| 1-year volatility | 32.2 % |
| Beta | 0.36 |
| 5-year max drawdown | -43.9 % |
| Sharpe 1A | -0.15 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.